| Literature DB >> 29022897 |
Junran Sun1,2, Peirong Huang1,2, Jian Liang3, Jie Li4, Mengxi Shen1,2, Xiangjun She1,2, Yiji Feng1,2, Xueting Luo3, Te Liu5,6, Xiaodong Sun1,2,3.
Abstract
Amyloid-beta (Aβ) is a hallmark component of age-related macular degeneration (AMD), which induces secretion of pro-inflammatory cytokines from retinal pigment epithelium (RPE). Previous studies have shown that p50/RelA (p65), a member of NF-κB family, is an essential pro-inflammatory transcription factor responding to Aβ1-40 stimulation, but few focused on the other two Rel transcription factor members - RelB and c-Rel - and their role in Aβ1-40-mediated inflammation. It was reported that RelA, RelB and c-Rel are also implicated in various NF-κB-mediated inflammatory diseases. Therefore, we infer that Aβ1-40-mediated inflammation targets not only the classical inflammation regulator, RelA, but also RelB and c-Rel. In this study, we demonstrate that intravitreally injected Aβ1-40 mice develop AMD-like pathologic changes, coupled with Rel protein (RelA, RelB and c-Rel) synthesis and nuclear translocation. To focus on the interaction mechanism of Rel proteins, we found that RelB and c-Rel formed a heterodimer with RelA in mice model. We also found that c-Rel silencing decreased the levels of Aβ1-40-dependent RelA expression, indicating that RelB and c-Rel may interact with RelA as coactivator and c-Rel is required to activate the expression of RelA. Moreover, Rel protein silencing decreased the expression of distinct pro-inflammatory cytokines. Together, we demonstrate that besides RelA, RelB and c-Rel can also be activated by Aβ1-40, all of which mediate pro-inflammatory cytokine transcription and RPE damage. Our findings imply that RPE-mediated inflammation under the stimulation of Aβ1-40 is multi-targeted and RelA, RelB and c-Rel proteins may be the new targets of anti-inflammatory agents.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29022897 PMCID: PMC5682668 DOI: 10.1038/cddis.2017.502
Source DB: PubMed Journal: Cell Death Dis Impact factor: 8.469
Figure 1Aβ1-40 induces RPE impairment and upregulates pro-inflammatory cytokine expression in vivo. C57BL/6 mice were injected intravitreally with 5 μl of 2.8 μg/μl Aβ1-40 (oligomeric form) or vehicle (PBS). (a) Immunoreactivity for Aβ1-40 was detected in the OS and RPE cells (arrows) at days 1 and 4 in the Aβ-injected sections. Scale bar: 50 μm. (b) TEM of the RPE and Bruch’s membrane regions in mice. Obvious thickening of the BrM and RPE basal in-foldings with ultrastructural alterations (Scale bar: 5 μm) was observed compared with that in the PBS-injected control mice (Scale bar: 1 μm). (c) Demonstration of waveforms of the maximal ERG response and amplitude evaluations of the scotopic ERG responses were recorded. (d) IL-1β, IL-18, IL-6, IL-8 and IL-12b mRNA expression levels in RPE–choroid in response to Aβ1-40 at day 4. BrM, Bruch’s membrane; CC, choriocapillaris; OS, outer segment. Histograms represent the mean and S.E.M. N=8, NS=nonsignificant P-value, *P<0.05, **P<0.01, ***P<0.001 via Student’s t-tests
Figure 2A time-dependent Rel protein expression pattern was induced by Aβ1-40 both in vivo and in vitro. (a) qRT-PCR assays of Rel gene expression in RPE–choroid complexes. Western blots showing time-dependent expression of Rel proteins in cytoplasmic (b) and nuclear extracts (c) of WT RPE–choroid complexes treated with 5 μl of 2.8 μg/μl Aβ1-40 or PBS (0, 2 and 4 days). Histone H3 was used as a quality control for the nuclear extracts. (d) Rel protein expression in mouse RPE cells in response to 5 μM Aβ1-40 at 6, 12 and 24 h after treatment. UT, untreated; WT, wild type. Histograms represent the mean and S.E.M. N=3, NS=nonsignificant P-value, *P<0.05, **P<0.01, ***P<0.001 via Student’s t-tests
Figure 3Rel protein translocation in RPE–choroid complexes and in primary mouse RPE cells. (a) Retinal sections co-immunostained with RPE65 (green) and RelB/c-Rel(red) at day 4. RPE nuclei were marked by white arrows (Scale bar: 20 μm). (b) Confocal microscopic analysis showing the distribution of the RelA/RelB/c-Rel signal (red) at 24 h after 5 μM Aβ1-40 or PBS treatment. Nuclei were immunostained with DAPI (blue) (Scale bar: 50 μm)
Figure 4The interaction between Rel proteins in RPE–choroid complex and in RPE cells. (a) RelA, RelB and c-Rel silencing induced changes in the RelA, RelB and c-Rel expression levels in ARPE-19 cells, as determined by qRT-PCR analysis. (b) qRT-PCR assays of Rel mRNA expression induced by RelA, RelB and c-Rel overexpression in primary mouse RPE cells. (c) Co-immunoprecipitation of c-Rel, RelB and RelA at 4 days post injection of Aβ1-40 or PBS. Histograms represent the mean and S.E.M. N=3, NS=nonsignificant P-value, *P<0.05, **P<0.01 via Student’s t-tests
Figure 5Effects of Rel protein silencing on pro-inflammatory cytokine levels in RPE cells. (a–f) ARPE-19 cells were transfected with only Lipofectamine 6000 reagent, non-siRNA, RelA siRNA, RelB siRNA or c-Rel siRNA for 24 h. IL-6 (a), IL-1β (b), IL-8 (c), IL-18 (d) and IL-12b (e) mRNA levels were evaluated by qRT-PCR. The mRNA levels were standardized to housekeeping gene expression. (f) Schematization of the model obtained by the integration of the data obtained in this report and the context. Histograms represent the mean and S.E.M. N=3, NS=nonsignificant P-value, *P<0.05, **P<0.01 Student’s t-tests
Quantitative RT-PCR primers
| Mouse GAPDH | 5′-CGGAGTCAACGGATTTGGTCGTAT-3′ | 5′-AGCCTTCTCCATGGTGGTGAAGAC-3′ |
| Mouse RelA | 5′-GCCCAGACCGCAGTATCC-3′ | 5′-GTCCCGCACTGTCACCTG-3′ |
| Mouse RelB | 5′-CTGGCTCCCTGAAGAACC-3′ | 5′-CGCTCTCCTTGTTGATTC-3′ |
| Mouse c-Rel | 5′-CTCTGCCTCCCATTGTTTCTA-3′ | 5′-GGCTTCCCAGTCATTCAACAC-3′ |
| Mouse IL-18 | 5′-CAGGCCTGACATCTTCTGCAA-3′ | 5′-CTGACATGGCAGCCATTGT-3′ |
| Mouse IL-1 | 5′-AGTTGACGGACCCCAAAAGAT-3′ | 5′-GTTGATGTGCTGCTGCGAGA-3′ |
| Mouse IL-8 | 5′-CAAGGCTGGTCCATGCTCC-3′ | 5′-TGCTATCACTTCCTTTCTGTTGC-3′ |
| Mouse IL-6 | 5′-CTTCCATCCAGTTGCCTTCTTG-3′ | 5′-AATTAAGCCTCCGACTTGTGAAG-3′ |
| Mouse IL-12b | 5′-ATGGAGTCATAGGCTCTGGAAA-3′ | 5′-CCGGAGTAATTTGGTGCTTCAC-3′ |
| Human GAPDH | 5′-TGTAGACCATGTAGTTGAGGTCA-3′ | 5′-AGGTCGGTGTGAACGGATTTG-3′ |
| Human RelA | 5′-CAGGCTCCTGTGCGTGTCTC-3′ | 5′-CTGGCTGATCTGCCCAGAAG-3′ |
| Human RelB | 5′-AGATTGAGGCTGCCATTGAG-3′ | 5′-CGCAGCTCTGATGTGTTTGT-3′ |
| Human c-Rel | 5′-CCATGTTCATCAGGGAGAAA-3′ | 5′-GCAGGAATCAATCCATTCAA-3′ |
| Human IL-18 | 5′-AGTCAGCAAGGAATTGTCTCC-3′ | 5′-GAAGCGATCTGGAAGGTCTG-3′ |
| Human IL-1 | 5′-TTACAGTGGCAATGAGGATGAC-3′ | 5′-TGTAGTGGTGGTCGGAGATTC-3′ |
| Human IL-8 | 5′-ATGACTTCCAAGCTGGCCGT-3′ | 5′-TCCTTGGCAAAACTGCACCT-3′ |
| Human IL-6 | 5′-GATGGCTGAAAAAGATGGATGC-3′ | 5′-TGGTTGGGTCAGGGGTGGTT-3′ |
| Human IL-12b | 5′-ACCTGACCCACCCAAGAACT-3′ | 5′-GGACCT GAACGCAGAATGTC-3′ |